Stephen N Mitchell

US Patent:

7803916, Sep 28, 2010

Filed:

Sep 16, 2008

Appl. No.:

12/211702

Inventors:

Daniel E. Afar - Fremont CA, US
Rene S. Hubert - Los Angeles CA, US
Stephen Chappell Mitchell - Gurnee IL, US

Assignee:

Agensys Inc. - Santa Monica CA

International Classification:

C07K 16/00
C12N 5/12

US Classification:

5303871, 5303971, 5303973, 435326

Abstract:

A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.

US Patent:

7981624, Jul 19, 2011

Filed:

Feb 19, 2009

Appl. No.:

12/389293

Inventors:

Daniel E. H. Afar - Fremont CA, US
Rene S. Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur B. Raitano - Los Angeles CA, US
Douglas Saffran - Encinitas CA, US
Stephen C. Mitchell - Gurnee IL, US
Aya Jakobovits - Beverly Hills CA, US
Mary Faris - Los Angeles CA, US
Igor Vivanco - Los Angeles CA, US

Assignee:

Agensys, Inc. - Santa Monica CA

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. ). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.

US Patent:

20060275304, Dec 7, 2006

Filed:

Aug 9, 2005

Appl. No.:

11/200973

Inventors:

Daniel Afar - Fremont CA, US
Rene Hubert - Los Angeles CA, US
Kahan Leong - Playa Del Rey CA, US
Arthur Raitano - Los Angeles CA, US
Douglas Saffran - Encinitas CA, US
Stephen Mitchell - Gurnee IL, US

Assignee:

AGENSYS, INC. - Santa Monica CA

International Classification:

A61K 39/395
C12Q 1/68
C07H 21/04
C12P 21/06
C07K 16/30
C07K 14/82
C07K 16/46

US Classification:

424155100, 435006000, 435069100, 435320100, 435325000, 530388800, 530350000, 424178100, 536023500

Abstract:

Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell surface serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. ). Among the compositions provides are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. Several monoclonal antibodies specifically reactive with 20P1F12/TMPRSS2 are also described herein.